丽珠医药(01513.HK) 公布,于2025年3月26日与丽珠生物订立2025增资协议,将以现金形式向丽珠生物增资10亿元人民币。于增资完成后,公司在丽珠生物的直接权益将由60.23%增加至66.54%。(gc/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-26 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.